Jubilant Ingrevia Limited has informed the Exchange about entering into the Share Purchase Agreement with Remidex Pharma Private Limited
JUBLINGREA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.6 pts less than Nifty Smallcap 250 and 0.5 pts less than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Jubilant Ingrevia has signed a Share Purchase Agreement to acquire 100% of Remidex Pharma Private Limited for Rs. 16.5 crore in cash, making it a wholly owned subsidiary. Remidex manufactures micronutrient premixes and nutraceuticals, and also works as a contract manufacturer for pharma companies, with a certified facility in Bangalore. The deal, expected to close within 30 days, needs no regulatory approvals and is not a related party transaction. This acquisition strengthens Jubilant Ingrevia's position in the Human Nutrition value chain, complementing its existing leadership in Vitamins B3 and B4. Remidex had a turnover of Rs. 24.27 crore in FY24-25, lower than Rs. 31.15 crore and Rs. 30.51 crore in the prior two years.
This is a small, tuck-in acquisition (Rs. 16.5 crore vs. a target turnover of ~Rs. 24 crore) that strategically extends Jubilant Ingrevia into the premix and nutraceuticals space without straining the balance sheet. For shareholders, it signals management's focus on expanding the nutrition portfolio, though the recent revenue decline at Remidex is a minor watchpoint.